These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 6867236)
1. A rating scale for tardive dyskinesia and Parkinsonian symptoms. Smith RC; Allen R; Gordon J; Wolff J Psychopharmacol Bull; 1983; 19(2):266-76. PubMed ID: 6867236 [No Abstract] [Full Text] [Related]
2. Current views on tardive dyskinesia. Gerlach J Pharmacopsychiatry; 1991 Mar; 24(2):47-8. PubMed ID: 1852791 [No Abstract] [Full Text] [Related]
4. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Lyons KE; Pahwa R Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814 [TBL] [Abstract][Full Text] [Related]
5. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008 [TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial. Linazasoro G Arch Neurol; 2007 Jan; 64(1):137-40. PubMed ID: 17210824 [No Abstract] [Full Text] [Related]
14. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable. Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663 [No Abstract] [Full Text] [Related]
15. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver H; Geraisy N; Schwartz M J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856 [TBL] [Abstract][Full Text] [Related]
16. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046 [TBL] [Abstract][Full Text] [Related]
17. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Brotchie JM Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137 [TBL] [Abstract][Full Text] [Related]